title: Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial.
abstract: OBJECTIVE
  The aim of this study was to evaluate the safety and improvement in quality of life using 10 mg and 5 mg daily doses of mifepristone for the treatment of uterine fibroids.
  
  
  METHODS
  The research was a randomized double-blind clinical study undertaken at the Eusebio Hernández Hospital in Havana, Cuba.
  
  
  METHODS
  Seventy subjects with symptomatic uterine fibroids took one daily capsule of 10 mg or 5 mg mifepristone orally for 9 months. One to three endometrial biopsies were performed. In evaluating safety, the variables studied were endometrial changes associated with mifepristone, elevation of hepatic transaminases, side effects of mifepristone, and instances and duration of irregular bleeding.
  
  
  RESULTS
  There were 30/49 (61.2%) and 13/24 (54.2%) diagnoses of endometrial changes associated with mifepristone in the 10 mg and 5 mg groups, respectively (P = 0.282). At every evaluation visit the average endometrial thickness was significantly greater in the 10 mg group than in the 5 mg group (P = 0.013, P = 0.002, and P = 0.013, respectively). Only five subjects had slight elevations in their hepatic transaminases after 9 months' treatment. Sixteen of 35 (45.7%) and eight of 33 (24.2%) subjects had the occasional hot flush in the 10 mg and 5 mg groups, respectively (P = 0.032). In total, there were 12.9 ± 4.6 (n = 21) and 9.1 ± 3.9 (n = 18) days of irregular bleeding in the 10 mg and 5 mg groups, respectively (P = 0.009).
  
  
  CONCLUSIONS
  According to the study findings, a 5 mg daily dose over 9 months has a relatively better safety profile than the 10 mg dose.
authors: Mediterránea Médica Clinic, Valencia, Spain.
authors: Josep Ll
authors: JL
authors: Carbonell
authors: Rita
authors: R
authors: Acosta
authors: Yasmiriam
authors: Y
authors: Pérez
authors: Ana G
authors: AG
authors: Marrero
authors: Edilia
authors: E
authors: Trellez
authors: Carlos
authors: C
authors: Sánchez
authors: Giuseppe
authors: G
authors: Tomasi
keywords: antiprogestins; fibroid; leiomyoma; mifepristone
references: Eur J Obstet Gynecol Reprod Biol. 2012 Apr;161(2):202-8
references: 22269473
references: Mod Pathol. 2008 May;21(5):591-8
references: 18246050
references: Hum Reprod Update. 2007 Nov-Dec;13(6):567-80
references: 17630398
references: Obstet Gynecol. 2002 Feb;99(2):290-300
references: 11814511
references: Hum Reprod. 2009 Aug;24(8):1870-9
references: 19389793
references: Zhonghua Fu Chan Ke Za Zhi. 1998 Aug;33(8):490-2
references: 10806751
references: J Clin Endocrinol Metab. 2002 Jan;87(1):63-70
references: 11788624
references: Aust N Z J Obstet Gynaecol. 2009 Feb;49(1):77-83
references: 19281585
references: Obstet Gynecol. 2006 Dec;108(6):1381-7
references: 17138770
references: Obstet Gynecol. 2008 Nov;112(5):1029-36
references: 18978102
references: Hum Pathol. 2011 Jul;42(7):947-53
references: 21315422
references: Hum Reprod. 2003 Jan;18(1):61-8
references: 12525442
references: Obstet Gynecol. 2003 Feb;101(2):243-50
references: 12576246
references: J Vasc Interv Radiol. 1999 Nov-Dec;10(10):1293-303
references: 10584643
references: Zhonghua Fu Chan Ke Za Zhi. 1996 Oct;31(10):624-6
references: 9275461
references: J Minim Invasive Gynecol. 2005 May-Jun;12(3):227-33
references: 15922980
references: Contraception. 2010 Nov;82(5):442-52
references: 20933118
references: Int J Womens Health. 2012;4:75-84
references: 22448109